Area Editoriale
Recombinanthuman erythropoietin has enjoyed a high profile status throughout its historyin medicine. The isolation and purification of erythropoietin and thesubsequent cloning of the human protein, followed by clinical trialsdemonstrating the reversal of anemia in renal dialysis patients in the 1980sushered in the era of biotechnology. In the 1990s, randomized clinical trialsdemonstrated that recombinant human erythropoietin was also effective in treatmentof anemia in cancer patients receiving chemotherapy. Subsequent open labeltrials described the impact of erythropoietic therapy in patients with anemiarelated to cancer chemotherapy.Leggil'articolo:è full text!